Back to journals
Academic JournalOpen Access

BMJ Open

4 Papers Indexed in Blossom

Data updated

Research Footprint

BMJ Open has 4 tracked papers indexed in Blossom (2010–2025) from 36 authors, most often covering Psilocybin and MDMA, across Depressive Disorders, Equity and Ethics and Major Depressive Disorder (MDD).

Published Papers

Paywallindividual

Psilocybin-assisted therapy for demoralisation in hospice patients: feasibility, safety and preliminary efficacy

In an open‑label pilot where 10 hospice patients received a single 25 mg psilocybin‑assisted therapy session, the intervention was feasible and well tolerated with no serious psilocybin‑related adverse events and produced a significant reduction in demoralisation at three weeks (mean reduction 8.8 points, p=0.0196). Acceptability varied because of the intervention’s emotional intensity, indicating PAT can be integrated into hospice care but requires optimisation and larger controlled trials.

Published
Journal
BMJ Open
Authors
Beaussant, Y., Sager, Z., Brennan, C., Kristan, I., Ljuslin, M., Mazzola, E., Macdonald, D., Murphy, M. E., Nigam, K., Rinaldi, A. D., Sanders, J., Schaefer, K. G., Sholevar, R., Summer, L., Waliji-Banglawala, A., Yudilevich-Espinoza, S., Tulsky, J. A.
Open Accessindividual

Psilocybin-assisted therapy for the treatment of resistant major depressive disorder (PsiDeR): protocol for a randomised, placebo-controlled feasibility trial

PsiDeR is a single-centre, randomised, placebo-controlled feasibility trial of psilocybin-assisted therapy in up to 60 people with treatment‑resistant major depressive disorder, testing a single 25 mg psilocybin dose plus psychological support with primary feasibility outcomes (recruitment, dropout and variance of the Montgomery–Åsberg Depression Rating Scale) at a 3‑week primary endpoint and 6‑week follow‑up. The protocol also collects optional neuroimaging and omics data for mechanism and biomarker analyses and offers an open‑label 25 mg psilocybin extension.

Published
Journal
BMJ Open
Authors
Rucker, J., Jafari, H., Mantingh, T., Bird, C., Modlin, N. L., Knight, G., Reinholdt, F., Day, C., Carter, B., Young, A.
Open Accessindividual

Does psychedelic drug use reduce risk of suicidality? Evidence from a longitudinal community-based cohort of marginalised women in a Canadian setting

In a longitudinal community-based cohort of marginalised women in Metro Vancouver, lifetime psychedelic drug use was associated with a 60% reduced hazard of incident suicidality over 54 months (adjusted HR 0.40), while crystal methamphetamine use and childhood abuse increased risk. These observational, naturalistic findings suggest a potential protective association of psychedelics and support further investigation of their therapeutic utility for mental health.

Published
Journal
BMJ Open
Authors
Argento, E., Strathdee, S. A., Tupper, K., Braschel, M., Wood, E., Shannon, K.
Open Accessindividual

Effects of a β-blocker on the cardiovascular response to MDMA (Ecstasy)

This double-blind cross-over study (n=16) finds that pindolol (medication for hypertension, 20mg) prevents the heart-raising effects of MDMA (112mg/70kg) but not the elevation of blood pressure.

Published
Journal
BMJ Open
Authors
Hysek, C. M., Vollenweider, F. X., Liechti, M. E.

Quick Facts

Papers Indexed
4
h-Index
176
Open Access
Yes
Publisher
BMJ
Country
United Kingdom
Website
Visit